Bone metabolism in thalassemia

Annals of the New York Academy of Sciences

Volumn 850, Issue , 1998, Pages 475-478

  Garofalo, F ^a   Piga, A ^a,c   Lala, R ^b   Chiabotto, S ^b   Di Stefano, M ^a   Isaia, G C ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Azienda Ospedaliera OIRM S   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ADOLESCENT; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CONFERENCE PAPER; DELAYED PUBERTY; DENSITOMETRY; FEMALE; GROWTH DISORDER; HORMONE DEFICIENCY; HUMAN; IRON CHELATION; LIFE EXPECTANCY; MALE; OSTEOBLAST; QUALITY OF LIFE; SCHOOL CHILD; THALASSEMIA;

EID: 0031853952     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10526.x     Document Type: Conference Paper

References (17)

1. GABUTTI, V. & A. PIGA. 1996. Results of long term iron-chelating therapy. Acta Haematol. 95: 26-36.
2. DE VERNEJOUL, M. C. et al. 1982. Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J. Clin. Endocrinol. Metabol. 54: 276-281.
3. ANAPLIOTOU, M. L. et al. 1995. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: New therapeutical approaches. Clin. Endocrinol. 42: 279-287.
4. DIAMOND, T. et al. 1989. Osteoporosis in haemocromatosis: Iron excess, gonadal deficiency or other factors? Ann. Int. Med. 110: 430-436.
5. JENSEN, C. E. et al. 1997. Incidence of enodcrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur. J. Haematol. 59(2): 76-81.
6. TANNER, J. M. et al. 1965. Standards from birth to maturity for height, weight, height velocity and weight velocity: British Children, 1965. Arch. Dis. Child. 41: 613-635.
7. GLASTRE, C. et al. 1990. Measurement of bone mineral content of the lumbar spine by Dual Energy X-Ray Absorptiometry in normal children: Correlations with growth parameters. J. Clin. Endocrinol. Metabol. 70: 1330-1333.
8. PANTELAKIS, S. 1994. Growth patterns in patients with thalassemia major. Acta Paediatr. Suppl. 406: 109-110.
9. DE SANCTIS, V. et al. 19943 Effect of different treatment regimens on linear growth and final height in β thalassemia major. Clin. Endocrinol. 40: 91.
10. ORVIETO, R. et al. 1992. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions and the treatment with desferrioxamine. Calcif. Tissue Int. 50: 397-399.
11. DINES, D. M. et al. 1976. Fractures in thalassemia. J. Bone Joint Surg. (a): 662-666.
12. FUJIMOTO, S. et al. 1995. Urinary pyridinoline and doexypyrydynoline in healthy children and in children with GH deficiency. J. Clin. Endocrinol. Metabol. 80: 1922-1928.
13. WEATHERAL, D. J. & J. B. CLEGG. 1981. The thalassemia syndromes. Blackwell Scientific Publications. Oxford, UK.
14. PIGA, A. et al. 1988. High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur. J. Haematol. 40: 380-381.
15. RODDA, C. P. et al. 1995. Short stature in homozygous β-thalassemia is due to disproportionate truncal shortening. Clin. Endocrinol. 42: 587-590.
16. BRILL, P. W. et al. 1991. Desferrioxamine-induced bone dysplasia in patients with thalassemia major. Am. J. Roetgenol. 156: 561-565.
17. HATORI, M., J. SPARKMAN, C. C. TEIXEIRA, M. GRYNPAS, J. NERVINA, N. OLIVIERI & I. M. SHAPIRO. 1995. Effects of deferoxamine on chondrocyte alkaline phosphatase activity: Prooxidant role of deferoxamine in thalassemia. Calcif. Tissue Int. 57: 229.